PDS Biotech Announces Up to $22.55 Million Financing for PDS0301
PDS Biotech will raise up to $22.55 million through a PIPE led by Nant Capital, including board representation for Nant. Proceeds will support late-stage development of its PDS0301 immunocytokine for solid tumors. The financing includes private placement share units and pre-funded warrant units with common warrants, with initial gross proceeds expected around $11.55 million.